Although, along with PD-L1, as reported above, microsatellite instability (MSI-H) and high tumor mutational burden (H-TMB) are tumor agonistic markers approved for the use of checkpoint inhibitors in solid tumors, their use in TNBC is minimal due to the very low rate of MSI-H and H-TMB. Here, CD274 is linked to neoplasm.